Summary
Eris Biotech develops small-molecule drugs that prevent tumors from releasing immune-suppressing vesicles, restoring the immune system's ability to fight cancer. Founded by Rachel Garlick and Evita Weagel, who both hold PhDs in immunology-related fields, they target cancer's immune evasion strategy rather than using toxic chemotherapy. Rachel previously developed novel therapies at a cell therapy startup, while Evita brought drugs to clinic in big pharma. They're starting with mesothelioma, which has a 5-year survival rate under 13 percent.
